Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Melanoma 74Neoplasm Metastasis 11Uveal Melanoma 7Skin Neoplasms 6Neoplasms 5Small Cell Lung Carcinoma 1Skin Diseases 1Sarcoma 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Parathyroid Neoplasms 1Oligodendroglioma 1Melanoma, Cutaneous Malignant 1Melanoma Neoplasms 1Lung Neoplasms 1Kidney Neoplasms 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Ependymoma 1Colonic Neoplasms 1Carcinoma 1Carcinoid Tumor 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1Advanced Melanoma 1

Interventions

pembrolizumab 6cemiplimab 3Cyclophosphamide 3temsirolimus 2palbociclib 2cediranib 2Therapeutics 2Radiotherapy 2Radiosurgery 2Psychiatric Rehabilitation 2Paclitaxel 2Oxaliplatin 2Nivolumab 2Methods 2Magnetic Resonance Spectroscopy 2Leucovorin 2Gemcitabine 2Fluorouracil 2Drug Therapy 2Docetaxel 2Cisplatin 2Capecitabine 2Biological Therapy 22,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1tanespimycin 1sonidegib 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × Dacarbazine × Dermatologic × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡